Anbio Biotechnology Showcases Diagnostic Tech at Healthcare Forum
安必生技於醫療論壇展出診斷技術
On March 18, 2026, Anbio Biotechnology took center stage at the KeyBanc Capital Markets Virtual Healthcare Forum.
2026年3月18日，安碧歐生物技術公司（Anbio Biotechnology）在KeyBanc資本市場虛擬醫療論壇（Virtual Healthcare Forum）上成為焦點。
Headquartered in Frankfurt, Germany, Anbio is dedicated to making diagnostics more decentralized, affordable, and accessible.
安碧歐總部位於德國法蘭克福（ㄈㄚˇㄌㄢˊㄎㄜˋㄈㄨˊ），致力於使診斷更加去中心化、實惠且易於獲取。
Since their February 2025 IPO on the NASDAQ, the company has focused on bridging cutting-edge R&D with the investor community.
自2025年2月在納斯達克（NASDAQ）首次公開募股（IPO）以來，該公司一直專注於連結尖端研發與投資者社群。
Anbio specializes in diverse diagnostic tools for point-of-care, laboratory, and over-the-counter settings, targeting everything from infectious diseases like SARS-CoV-2 to chronic conditions such as cardiovascular disease.
安碧歐專精於各類臨床現場（Point-of-care）、實驗室及成藥（OTC）環境下的診斷工具，應用範圍涵蓋從如SARS-CoV-2般的傳染病，到心血管疾病等慢性病。
Their technological portfolio is impressive, featuring the high-precision ADL-1000 "Dry CLIA" solution and portable fluorescence immunoassay (FIA) devices like the AF-100S.
他們的技術組合令人印象深刻，包括高精度的ADL-1000「乾式化學發光（Dry CLIA）」解決方案，以及如AF-100S等可攜式螢光免疫分析（FIA）設備。
While Anbio continues to expand its global footprint through strategic partnerships, it faces significant challenges, including navigating the EU’s strict In Vitro Diagnostic Regulation (IVDR) and pursuing FDA clearances in the United States.
儘管安碧歐持續透過戰略合作擴大其全球足跡，但仍面臨重大挑戰，包括如何應對歐盟嚴格的《體外診斷醫療器材法規》（IVDR），以及在美國爭取FDA許可。
